Valuation: Mineralys Therapeutics, Inc.

Market Cap 2.35B 2.07B 1.92B 1.76B 3.32B 227B 3.37B 22.84B 8.92B 111B 8.84B 8.65B 385B P/E 2026 *
-11.6x
P/E 2027 * -12.6x
Enterprise Value 2.17B 1.91B 1.77B 1.63B 3.06B 209B 3.1B 21.06B 8.23B 103B 8.15B 7.97B 355B EV / Sales 2026 *
-
EV / Sales 2027 * 17.7x
Free-Float
97.63%
Yield 2026 *
-
Yield 2027 * -
1 day-1.07%
1 week-1.40%
Current month-1.00%
1 month+3.63%
3 months-2.91%
6 months-18.52%
Current year-26.40%
1 week 25.92
Extreme 25.92
27.98
1 month 25.44
Extreme 25.44
31.11
Current year 22.3
Extreme 22.3
37.7
1 year 12.59
Extreme 12.59
47.65
3 years 5.85
Extreme 5.85
47.65
5 years 5.85
Extreme 5.85
47.65
10 years 5.85
Extreme 5.85
47.65
Manager TitleAgeSince
Chief Executive Officer 62 2020-10-31
Director of Finance/CFO 48 2022-02-28
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 62 -
Chairman 49 2019-05-30
Director/Board Member 58 2021-01-31
Date Insider Type Main position Quantity % Market Cap.
7/21/26 Fiscal year

Chief Commercial Officer

22,314 0.0253%
7/17/26 Fiscal year

Chief Technology Officer

1,248 0.0014%
7/15/26 Sell

Chief Technology Officer

-6,349 0.0072%
Change 5-day change 1-year change 3-year change Capi.($)
-1.07%-1.40%+87.31%+79.02% 2.35B
+1.07%-3.49%-3.25%+12.87% 46.86B
+0.25%+1.65%+408.41%+629.49% 40.23B
-0.27%+4.45%+9.93%+66.92% 36.23B
+0.35%+0.87%+3.60%-8.81% 34.72B
+3.14%+1.02%+3.37%+38.15% 27.89B
-0.73%+11.84%+31.97%+143.53% 16.79B
+0.47%-2.74% - - 16.74B
+0.42%-5.52%+0.76%+8.50% 13.12B
-2.68%-2.49%-15.00%-31.68% 12.7B
Average +0.09%+0.61%+58.57%+104.22% 24.76B
Weighted average by Cap. +0.46%+0.89%+75.44%+136.06%

Financials

2026 *2027 *
Net sales - 121M 107M 99.15M 90.98M 171M 11.69B 174M 1.18B 460M 5.75B 456M 446M 19.87B
Net income -193M -169M -158M -145M -272M -18.58B -276M -1.87B -731M -9.14B -724M -709M -31.59B -184M -162M -150M -138M -259M -17.74B -263M -1.79B -698M -8.72B -691M -676M -30.15B
Net Debt -184M -161M -150M -138M -259M -17.69B -263M -1.78B -696M -8.7B -690M -675M -30.07B -209M -183M -170M -156M -294M -20.1B -298M -2.02B -791M -9.88B -783M -767M -34.16B
Logo Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc. is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone. Its product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as CKD and OSA. Lorundrostat is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone. It has completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uncontrolled hypertension (uHTN) and resistant hypertension (rHTN). It is also investigating the benefits of lorundrostat in subjects with hypertension and CKD and with hypertension and OSA.
Employees
76
Date Price Change Volume
26-07-24 US$26.71 -1.07% 648,860
26-07-23 US$27.00 -0.04% 853,555
26-07-22 US$27.01 -1.85% 506,855
26-07-21 US$27.52 +3.03% 456,634
26-07-20 US$26.71 -1.40% 501,005
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
26.71USD
Average target price
49.00USD
Spread / Average Target
+83.45%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MLYS Stock